Monitor for updates on the ongoing Phase 3 trials (ROSETTA Lung-01, -02, -201, -202) and any regulatory interactions regarding pumitamig in second-line NSCLC. The ROSETTA Lung-107 data will inform the path forward for this indication.
Price Chart
Executive Summary
BioNTech and Bristol Myers Squibb reported encouraging Phase 2 data from the ROSETTA Lung-107 trial evaluating pumitamig plus docetaxel in second-line metastatic NSCLC. The combination showed a confirmed objective response rate of 36.7% and median progression-free survival of 6.9 months, compared to historical standard-of-care docetaxel PFS of ~3.6-3.9 months. The data were presented at ESMO 2026 and represent the third global Phase 2 dataset for pumitamig in lung cancer.
Key Facts
- Phase 2 ROSETTA Lung-107 trial (NCT06841055) evaluating pumitamig + docetaxel in metastatic NSCLC after progression on first-line immunotherapy plus chemotherapy
- Confirmed objective response rate (cORR) of 36.7% and disease control rate (DCR) of 90.0% among 30 efficacy-evaluable patients
- Median progression-free survival (PFS) of 6.9 months (95% CI 4.2 - not reached) vs historical standard-of-care docetaxel PFS of ~3.6-3.9 months
- Responses observed across PD-L1 expression levels (cORR 42.9% TPS <1%, 33.3% TPS 1-49%, 40.0% TPS ≥50%) and histologies (cORR 57.1% squamous, 30.4% non-squamous)
- Manageable safety profile with no new safety signals; grade 3 treatment-related AEs in 18.0% of patients, no pumitamig-related deaths or dose-limiting toxicities
- Data presented at ESMO Congress 2026 in Madrid (abstract #LBA76)
- Seven global Phase 3 trials with registrational potential are ongoing for pumitamig across multiple cancer types
Financial Impact
No financial figures provided in the filing. The data supports continued development of pumitamig in second-line NSCLC, a high-unmet-need market. BioNTech's market cap is $22.5B.
Risk Factors
- Phase 2 data are from a single-arm, open-label trial with a small sample size (50 patients, 30 efficacy-evaluable); results may not replicate in larger randomized Phase 3 trials
- Median follow-up was only 12.2 weeks; durability of responses and overall survival data are immature
- Pumitamig is investigational and not yet approved; regulatory approval is uncertain and may take years
- Competition from other PD-L1xVEGF bispecifics and standard-of-care therapies could limit commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000076 |
| Document: form6-krosettalung107data2.htm | 0001776985-26-000076 |
| Document: 0001776985-26-000076-index-headers.html | 0001776985-26-000076 |
| Document: 0001776985-26-000076-index.html | 0001776985-26-000076 |
| Document: 0001776985-26-000076.txt | 0001776985-26-000076 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $86.86 | awaiting T+60 | — | $87.06 (+0.23%) |
Oct 26, 2026 1d ago | 6-K | $86.86 | awaiting T+60 | — | $87.06 (−0.23%) |
Oct 26, 2026 1d ago | Press Release | $86.86 | awaiting T+60 | — | $87.06 (−0.23%) |
Oct 25, 2026 2d ago | Press Release | $86.86 | awaiting T+60 | — | $87.06 (+0.23%) |
Oct 22, 2026 5d ago | 6-K | $89.67 | awaiting T+60 | — | $87.06 (−2.91%) |
Oct 19, 2026 8d ago | 6-K | $89.21 | awaiting T+60 | — | $87.06 (−2.41%) |
Oct 19, 2026 8d ago | Press Release | $89.21 | awaiting T+60 | — | $87.06 (−2.41%) |
Oct 13, 2026 14d ago | 6-K | $88.66 | awaiting T+60 | — | $87.06 (+1.80%) |
Sep 14, 2026 6w ago | 6-K | $98.86 | awaiting T+60 | — | $87.06 (−11.94%) |
Sep 14, 2026 6w ago | Press Release | $98.86 | awaiting T+60 | — | $87.06 (−11.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers